1035 related articles for article (PubMed ID: 32627689)
1. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
2. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
Purohit P; Dash JJ; Muya JT; Meher BR
J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
[TBL] [Abstract][Full Text] [Related]
3.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
4. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.
Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B
J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950
[TBL] [Abstract][Full Text] [Related]
5. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
[TBL] [Abstract][Full Text] [Related]
6. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
[TBL] [Abstract][Full Text] [Related]
7. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
8.
Ibrahim MAA; Abdelrahman AHM; Hegazy MF
J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
[TBL] [Abstract][Full Text] [Related]
9. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
[TBL] [Abstract][Full Text] [Related]
10. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
11. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
12. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
13. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 M
Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
[TBL] [Abstract][Full Text] [Related]
15. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.
Sajid Jamal QM; Alharbi AH; Ahmad V
J Biomol Struct Dyn; 2022 Oct; 40(17):7960-7974. PubMed ID: 33826483
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
17. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S
J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129
[TBL] [Abstract][Full Text] [Related]
18. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
19. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
20. Identification of bioactive molecule from
Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
